Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pietro Ghezzi

Showing results (131-140 of 149) with videos related to

Pageof 15
Sort By:
Antioxidants & Redox Signaling|September 29, 2015
Pharmacology and Clinical Drug Candidates in Redox MedicineV Thao-Vi Dao, Ana I Casas, Ghassan J Maghzal, et al.
Molecular Medicine (Cambridge, Mass.)|November 8, 2006
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivoTiziana Mennini, Massimiliano De Paola, Paolo Bigini, et al.
Journal of Neuroimmunology|December 13, 2005
Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitisCostanza Savino, Rosetta Pedotti, Fulvio Baggi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growthRoberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2004
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptorMichael Brines, Giovanni Grasso, Fabio Fiordaliso, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2008
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinMichael Brines, Nimesh S A Patel, Pia Villa, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2014
Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signalSonia Salzano, Paola Checconi, Eva-Maria Hanschmann, et al.
Antioxidants & Redox Signaling|November 20, 2015
Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsAna I Casas, V Thao-Vi Dao, Andreas Daiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesThomas R Coleman, Christof Westenfelder, Florian E Tögel, et al.
Pharmacological Reviews|March 7, 2018
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine ApproachAntonio Cuadrado, Gina Manda, Ahmed Hassan, et al.
Pageof 15

Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Antioxidants & Redox Signaling|September 29, 2015
Pharmacology and Clinical Drug Candidates in Redox MedicineV Thao-Vi Dao, Ana I Casas, Ghassan J Maghzal, et al.
Molecular Medicine (Cambridge, Mass.)|November 8, 2006
Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivoTiziana Mennini, Massimiliano De Paola, Paolo Bigini, et al.
Journal of Neuroimmunology|December 13, 2005
Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitisCostanza Savino, Rosetta Pedotti, Fulvio Baggi, et al.
European Journal of Cancer (Oxford, England : 1990)|January 26, 2007
Cisplatin-induced peripheral neuropathy: neuroprotection by erythropoietin without affecting tumour growthRoberto Bianchi, Alessandra Gilardini, Virginia Rodriguez-Menendez, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 2004
Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptorMichael Brines, Giovanni Grasso, Fabio Fiordaliso, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 5, 2008
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinMichael Brines, Nimesh S A Patel, Pia Villa, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 7, 2014
Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signalSonia Salzano, Paola Checconi, Eva-Maria Hanschmann, et al.
Antioxidants & Redox Signaling|November 20, 2015
Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsAna I Casas, V Thao-Vi Dao, Andreas Daiber, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 6, 2006
Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activitiesThomas R Coleman, Christof Westenfelder, Florian E Tögel, et al.
Pharmacological Reviews|March 7, 2018
Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine ApproachAntonio Cuadrado, Gina Manda, Ahmed Hassan, et al.
Pageof 15